OUTCOME OF HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NON-HODGKIN LYMPHOMA
(Abstract release date: 05/19/16)
EHA Library. Xu T. 06/09/16; 135050; PB2150
Prof. Dr. Ting Xu
Contributions
Contributions
Abstract
Abstract: PB2150
Type: Publication Only
Background
Patients with non-Hodgkin lymphoma (NHL) who have relapsed or refractory disease, may not achieve long-term disease-free (DFS) even after autologous hematopoietic stem cell transplantation (auto-HSCT). The long-term survival or curability is still challenging. Given this situation, allogeneic (allo)-HSCT for the treatment of aggressive、relapsed or refractory NHL is appealing for the prospect of providing both a tumour-free graft and the graft-versus-lymphoma (GVL) effect. However, there have been only limited matched sibling dornor for allo-HSCT. For those patients who do not have suitable dornors, the related partially HLA-matched dornors may be a good choice. Related haploidentical (haplo)-HSCT may offer the opportunity to achieve long-term survival and cure for those select patients.
Aims
To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation(HSCT) for refractory、relapsed or highly aggressive non-hodgkin lymphoma(NHL) patients.
Methods
26 refractory、relapsed or highly aggressive NHL patients who received haploidentical HSCT from Jan 2004 to Mar 2015 were analyzed retrospectively. 17 patients were treated with the conditioning regimen consisting of modified busulfan/cyclophosphamide(Bu/Cy) plus anti-human thymocyte globulin(ATG). 9 patients were given the regimen comprised of total body irradiation(TBI)/Cy plus ATG. All patients were pretreated with cyclosporin A(CsA)、methotrexate(MTX)、mycophenolate mofetil(MMF) and ATG to prevent graft-versus-host disease(GVHD).
Results
The patients included 4 cases of diffuse large B-cell lymphoma, 1 case of follicular lymphoma, 5 cases of B-lymphoblastic lymphoma/leukemia, 9 cases of T- lymphoblastic lymphoma/leukemia, 1 case of anaplastic large cell lymphoma(ALK-), 5 cases of peripheral T-cell lymphoma(NOS), and 1 case of NK/T-cell lymphoma. 19 patients were refractory or relapsed. All patients achieved full donor chimerism. With a median follow-up of 13.5(4-136) months, 20 cases(76.92%) survived, 15(57.69%) survived without lymphoma, and 7(26.92%) relapsed. 6 patients died, 4 because of recurrence/progress, 2 because of the complication of HSCT. 8 patients developed acute GVHD grades Ⅱ-Ⅳ, which risk at 100 days was 30.80%. The risk of chronic GVHD at 2 years was 25.10%. The estimated 2-year recurrence rate was 42.20%. The estimated 1-year overall survival(OS) and disease-free survival(DFS) rate was 84.60% and 61.10%, respectively. The 2-year OS and DFS rate was 71.60% and 48.90%, respectively. Univariate analysis showed that disease status (complete remission/ not complete remission) before haploidentical HSCT may be a factor affecting OS and DFS.
Conclusion
Haploidentical HSCT is effective for relapsed、refractory or highly aggressive NHL. It may prolong DFS in part of those patients and even cure them.
Session topic: E-poster
Keyword(s): Haploidentical stem cell transplantation, Non-Hodgkin's lymphoma
Type: Publication Only
Background
Patients with non-Hodgkin lymphoma (NHL) who have relapsed or refractory disease, may not achieve long-term disease-free (DFS) even after autologous hematopoietic stem cell transplantation (auto-HSCT). The long-term survival or curability is still challenging. Given this situation, allogeneic (allo)-HSCT for the treatment of aggressive、relapsed or refractory NHL is appealing for the prospect of providing both a tumour-free graft and the graft-versus-lymphoma (GVL) effect. However, there have been only limited matched sibling dornor for allo-HSCT. For those patients who do not have suitable dornors, the related partially HLA-matched dornors may be a good choice. Related haploidentical (haplo)-HSCT may offer the opportunity to achieve long-term survival and cure for those select patients.
Aims
To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation(HSCT) for refractory、relapsed or highly aggressive non-hodgkin lymphoma(NHL) patients.
Methods
26 refractory、relapsed or highly aggressive NHL patients who received haploidentical HSCT from Jan 2004 to Mar 2015 were analyzed retrospectively. 17 patients were treated with the conditioning regimen consisting of modified busulfan/cyclophosphamide(Bu/Cy) plus anti-human thymocyte globulin(ATG). 9 patients were given the regimen comprised of total body irradiation(TBI)/Cy plus ATG. All patients were pretreated with cyclosporin A(CsA)、methotrexate(MTX)、mycophenolate mofetil(MMF) and ATG to prevent graft-versus-host disease(GVHD).
Results
The patients included 4 cases of diffuse large B-cell lymphoma, 1 case of follicular lymphoma, 5 cases of B-lymphoblastic lymphoma/leukemia, 9 cases of T- lymphoblastic lymphoma/leukemia, 1 case of anaplastic large cell lymphoma(ALK-), 5 cases of peripheral T-cell lymphoma(NOS), and 1 case of NK/T-cell lymphoma. 19 patients were refractory or relapsed. All patients achieved full donor chimerism. With a median follow-up of 13.5(4-136) months, 20 cases(76.92%) survived, 15(57.69%) survived without lymphoma, and 7(26.92%) relapsed. 6 patients died, 4 because of recurrence/progress, 2 because of the complication of HSCT. 8 patients developed acute GVHD grades Ⅱ-Ⅳ, which risk at 100 days was 30.80%. The risk of chronic GVHD at 2 years was 25.10%. The estimated 2-year recurrence rate was 42.20%. The estimated 1-year overall survival(OS) and disease-free survival(DFS) rate was 84.60% and 61.10%, respectively. The 2-year OS and DFS rate was 71.60% and 48.90%, respectively. Univariate analysis showed that disease status (complete remission/ not complete remission) before haploidentical HSCT may be a factor affecting OS and DFS.
Conclusion
Haploidentical HSCT is effective for relapsed、refractory or highly aggressive NHL. It may prolong DFS in part of those patients and even cure them.
Session topic: E-poster
Keyword(s): Haploidentical stem cell transplantation, Non-Hodgkin's lymphoma
Abstract: PB2150
Type: Publication Only
Background
Patients with non-Hodgkin lymphoma (NHL) who have relapsed or refractory disease, may not achieve long-term disease-free (DFS) even after autologous hematopoietic stem cell transplantation (auto-HSCT). The long-term survival or curability is still challenging. Given this situation, allogeneic (allo)-HSCT for the treatment of aggressive、relapsed or refractory NHL is appealing for the prospect of providing both a tumour-free graft and the graft-versus-lymphoma (GVL) effect. However, there have been only limited matched sibling dornor for allo-HSCT. For those patients who do not have suitable dornors, the related partially HLA-matched dornors may be a good choice. Related haploidentical (haplo)-HSCT may offer the opportunity to achieve long-term survival and cure for those select patients.
Aims
To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation(HSCT) for refractory、relapsed or highly aggressive non-hodgkin lymphoma(NHL) patients.
Methods
26 refractory、relapsed or highly aggressive NHL patients who received haploidentical HSCT from Jan 2004 to Mar 2015 were analyzed retrospectively. 17 patients were treated with the conditioning regimen consisting of modified busulfan/cyclophosphamide(Bu/Cy) plus anti-human thymocyte globulin(ATG). 9 patients were given the regimen comprised of total body irradiation(TBI)/Cy plus ATG. All patients were pretreated with cyclosporin A(CsA)、methotrexate(MTX)、mycophenolate mofetil(MMF) and ATG to prevent graft-versus-host disease(GVHD).
Results
The patients included 4 cases of diffuse large B-cell lymphoma, 1 case of follicular lymphoma, 5 cases of B-lymphoblastic lymphoma/leukemia, 9 cases of T- lymphoblastic lymphoma/leukemia, 1 case of anaplastic large cell lymphoma(ALK-), 5 cases of peripheral T-cell lymphoma(NOS), and 1 case of NK/T-cell lymphoma. 19 patients were refractory or relapsed. All patients achieved full donor chimerism. With a median follow-up of 13.5(4-136) months, 20 cases(76.92%) survived, 15(57.69%) survived without lymphoma, and 7(26.92%) relapsed. 6 patients died, 4 because of recurrence/progress, 2 because of the complication of HSCT. 8 patients developed acute GVHD grades Ⅱ-Ⅳ, which risk at 100 days was 30.80%. The risk of chronic GVHD at 2 years was 25.10%. The estimated 2-year recurrence rate was 42.20%. The estimated 1-year overall survival(OS) and disease-free survival(DFS) rate was 84.60% and 61.10%, respectively. The 2-year OS and DFS rate was 71.60% and 48.90%, respectively. Univariate analysis showed that disease status (complete remission/ not complete remission) before haploidentical HSCT may be a factor affecting OS and DFS.
Conclusion
Haploidentical HSCT is effective for relapsed、refractory or highly aggressive NHL. It may prolong DFS in part of those patients and even cure them.
Session topic: E-poster
Keyword(s): Haploidentical stem cell transplantation, Non-Hodgkin's lymphoma
Type: Publication Only
Background
Patients with non-Hodgkin lymphoma (NHL) who have relapsed or refractory disease, may not achieve long-term disease-free (DFS) even after autologous hematopoietic stem cell transplantation (auto-HSCT). The long-term survival or curability is still challenging. Given this situation, allogeneic (allo)-HSCT for the treatment of aggressive、relapsed or refractory NHL is appealing for the prospect of providing both a tumour-free graft and the graft-versus-lymphoma (GVL) effect. However, there have been only limited matched sibling dornor for allo-HSCT. For those patients who do not have suitable dornors, the related partially HLA-matched dornors may be a good choice. Related haploidentical (haplo)-HSCT may offer the opportunity to achieve long-term survival and cure for those select patients.
Aims
To explore the efficacy and safety of haploidentical hematopoietic stem cell transplantation(HSCT) for refractory、relapsed or highly aggressive non-hodgkin lymphoma(NHL) patients.
Methods
26 refractory、relapsed or highly aggressive NHL patients who received haploidentical HSCT from Jan 2004 to Mar 2015 were analyzed retrospectively. 17 patients were treated with the conditioning regimen consisting of modified busulfan/cyclophosphamide(Bu/Cy) plus anti-human thymocyte globulin(ATG). 9 patients were given the regimen comprised of total body irradiation(TBI)/Cy plus ATG. All patients were pretreated with cyclosporin A(CsA)、methotrexate(MTX)、mycophenolate mofetil(MMF) and ATG to prevent graft-versus-host disease(GVHD).
Results
The patients included 4 cases of diffuse large B-cell lymphoma, 1 case of follicular lymphoma, 5 cases of B-lymphoblastic lymphoma/leukemia, 9 cases of T- lymphoblastic lymphoma/leukemia, 1 case of anaplastic large cell lymphoma(ALK-), 5 cases of peripheral T-cell lymphoma(NOS), and 1 case of NK/T-cell lymphoma. 19 patients were refractory or relapsed. All patients achieved full donor chimerism. With a median follow-up of 13.5(4-136) months, 20 cases(76.92%) survived, 15(57.69%) survived without lymphoma, and 7(26.92%) relapsed. 6 patients died, 4 because of recurrence/progress, 2 because of the complication of HSCT. 8 patients developed acute GVHD grades Ⅱ-Ⅳ, which risk at 100 days was 30.80%. The risk of chronic GVHD at 2 years was 25.10%. The estimated 2-year recurrence rate was 42.20%. The estimated 1-year overall survival(OS) and disease-free survival(DFS) rate was 84.60% and 61.10%, respectively. The 2-year OS and DFS rate was 71.60% and 48.90%, respectively. Univariate analysis showed that disease status (complete remission/ not complete remission) before haploidentical HSCT may be a factor affecting OS and DFS.
Conclusion
Haploidentical HSCT is effective for relapsed、refractory or highly aggressive NHL. It may prolong DFS in part of those patients and even cure them.
Session topic: E-poster
Keyword(s): Haploidentical stem cell transplantation, Non-Hodgkin's lymphoma
{{ help_message }}
{{filter}}